Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Iteos Therapeutics Inc (ITOS)
Iteos Therapeutics Inc (ITOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 380,931
  • Shares Outstanding, K 35,785
  • Annual Sales, $ 267,630 K
  • Annual Income, $ 96,650 K
  • 60-Month Beta 1.14
  • Price/Sales 5.79
  • Price/Cash Flow 3.92
  • Price/Book 0.63
Trade ITOS with:

Options Overview Details

View History
  • Implied Volatility 77.68% ( -11.25%)
  • Historical Volatility 56.95%
  • IV Percentile 47%
  • IV Rank 40.03%
  • IV High 140.47% on 12/21/23
  • IV Low 35.77% on 12/12/23
  • Put/Call Vol Ratio 6.60
  • Today's Volume 38
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 1,679
  • Open Int (30-Day) 1,578

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.03
  • Number of Estimates 5
  • High Estimate -0.08
  • Low Estimate -1.83
  • Prior Year 0.57
  • Growth Rate Est. (year over year) -280.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.70 +9.74%
on 02/16/24
11.12 -4.27%
on 02/12/24
+0.42 (+4.06%)
since 01/23/24
3-Month
8.95 +18.94%
on 12/01/23
11.83 -10.02%
on 01/03/24
+0.95 (+9.74%)
since 11/22/23
52-Week
8.20 +29.82%
on 10/12/23
18.24 -41.64%
on 05/26/23
-7.65 (-41.83%)
since 02/23/23

Most Recent Stories

More News
NCR Atleos Set to Join S&P SmallCap 600

/PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of...

SPGI : 438.27 (+0.70%)
ITOS : 10.65 (+7.42%)
NATL : 21.07 (+1.79%)
NCR : 27.08 (+3.24%)
VYX : 15.04 (+2.80%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – June 8, 2023 – USA News Group  –  By utilizing newly developed novel mechanisms, biotech researchers and scientists are...

ONCY : 0.9869 (-4.65%)
ONC.TO : 1.35 (-3.57%)
GILD : 73.55 (+1.06%)
ITOS : 10.65 (+7.42%)
GSK : 42.22 (+0.14%)
PGEN : 1.4600 (+1.39%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

/PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against...

ONC.TO : 1.35 (-3.57%)
ONCY : 0.9869 (-4.65%)
GILD : 73.55 (+1.06%)
ITOS : 10.65 (+7.42%)
GSK : 42.22 (+0.14%)
PGEN : 1.4600 (+1.39%)
Novel Mechanisms Leading the Charge in Fight Against Cancer, Opening Door to New Drugs & Therapies

USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of...

ONCY : 0.9869 (-4.65%)
ONC.TO : 1.35 (-3.57%)
GILD : 73.55 (+1.06%)
ITOS : 10.65 (+7.42%)
GSK : 42.22 (+0.14%)
PGEN : 1.4600 (+1.39%)
ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 55.56% and 8.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ITOS : 10.65 (+7.42%)
GERN : 1.9600 (-0.51%)
Bluebird Bio (BLUE) Q1 Earnings Surpass Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of 138.89% and 89.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BLUE : 1.2500 (+5.93%)
ITOS : 10.65 (+7.42%)
Dynavax Technologies (DVAX) Reports Q1 Loss, Tops Revenue Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -58.33% and 21.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DVAX : 12.75 (+2.49%)
ITOS : 10.65 (+7.42%)
ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

ITOS : 10.65 (+7.42%)
LVTX : 2.07 (+1.97%)
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -4.76% and 15.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

RNA : 14.04 (-3.44%)
ITOS : 10.65 (+7.42%)
ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -57.14% and 53.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

ITOS : 10.65 (+7.42%)
PDCO : 28.80 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology therapeutics. iTeos Therapeutics Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 11.70
2nd Resistance Point 11.18
1st Resistance Point 10.91
Last Price 10.65
1st Support Level 10.12
2nd Support Level 9.60
3rd Support Level 9.33

See More

52-Week High 18.24
Fibonacci 61.8% 14.40
Fibonacci 50% 13.22
Fibonacci 38.2% 12.04
Last Price 10.65
52-Week Low 8.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar